An open source pharma roadmap
Manica Balasegaram(Global Antibiotic Research & Development Partnership), John Wilbanks(Sage Bionetworks), John C. McKew(National Institutes of Health), Peter Kolb(Philipps University of Marburg), Piero Olliaro(University of Oxford), Els Torreele(Instituut voor Landbouw en Visserijonderzoek), Matthew H. Todd(Structural Genomics Consortium), Zakir Thomas(Council of Scientific and Industrial Research), Tomasz Sablinski(Icahn School of Medicine at Mount Sinai), Jaykumar Menon(McGill University)
Cited by 52
Related Papers
Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol
|The Lancet Regional Health - Europe|2021|322
GPCRmd uncovers the dynamics of the 3D-GPCRome
|Nature Methods|2020|199
REMOVAL OF ANTI-PORCINE NATURAL ANTIBODIES FROM HUMAN AND NONHUMAN PRIMATE PLASMA IN VITRO AND IN VIVO BY A Gal??1-3Gal??1-4??Glc-X IMMUNOAFFINITY COLUMN
|Transplantation|1998|196
Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial
|The Lancet|2000|189
Randomised controlled trials for Ebola: practical and ethical issues
|The Lancet|2014|182